Pemphigus vulgaris

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pemphigus vulgaris
Pemphigus vulgaris - intermed mag.jpg
Micrograph of pemphigus vulgaris with the characteristic "tombstoning". H&E stain.
Specialty Dermatology Edit this on Wikidata

Pemphigus vulgaris is a rare chronic blistering skin disease and the most common form of pemphigus. Pemphigus was derived from the Greek word pemphix, meaning blister.[1] It is classified as a type II hypersensitivity reaction in which antibodies are formed against desmosomes, components of the skin that function to keep certain layers of skin bound to each other. As desmosomes are attacked, the layers of skin separate and the clinical picture resembles a blister. These blisters are due to acatholysis, or breaking apart of intercellular connections through an autoantibody-mediated response.[2] Over time the condition inevitably progresses without treatment: lesions increase in size and distribution throughout the body, behaving physiologically like a severe burn.

Before the advent of modern treatments, mortality for the disease was close to 90%. Today, the mortality rate with treatment is between 5-15% due to the introduction of corticosteroids as primary treatment.[3] Nevertheless, in 1998, pemphigus vulgaris was the fourth most common cause of death due to a skin disorder.

Although this disease mainly targets middle-aged and older adults between 50–60 years old, there has historically been a higher incidence in women.[4]

Signs and symptoms[edit]

Pemphigus vulgaris most commonly presents with oral blisters (buccal and palatine mucosa, especially), but also includes cutaneous blisters. Other mucosal surfaces, the conjunctiva, nose, esophagus, penis, vulva, vagina, cervix, and anus, may also be affected. Flaccid blisters over the skin are frequently seen with sparing of the skin covering the palms and soles.[5]

Blisters commonly erode and leave ulcerated lesions and erosions. A positive Nikolsky sign (induction of blistering in normal skin or at the edge of a blister) is indicative of the disease.[5]

Severe pain with chewing can lead to weight loss and malnutrition.[5]

Pemphigus vulgaris (PV) is a life-threatening chronic autoimmune disease where the serum autoantibodies respond to the cell surface antigens resulting in a loss of epidermal cell cohesion [1]. This can be characterized as the manifestation of circulatingautoantibodies against the intercellular adhesion structures, desmosomal protein desmoglein (DSG) 3, and in some cases DSG1.[6][7]

Pathophysiology[edit]

Pemphigus is an autoimmune disease caused by antibodies directed against both desmoglein 1 and desmoglein 3 present in desmosomes. Loss of desmosomes results in loss of cohesion between keratinocytes in the epidermis, and a disruption of the barrier function served by intact skin. The process is classified as a type II hypersensitivity reaction (in which antibodies bind to antigens on the body's own tissues). On histology, the basal keratinocytes are usually still attached to the basement membrane leading to a characteristic appearance called "tombstoning." Transudative fluid accumulates in between the keratinocytes and the basal layer (suprabasal split), forming a blister and resulting in what is known as a positive Nikolsky's sign. This is a contrasting feature from bullous pemphigoid, which is thought to be due to anti-hemidesmosome antibodies, and where the detachment occurs between the epidermis and dermis (subepidermal bullae). Clinically, pemphigus vulgaris is characterized by extensive flaccid blisters and mucocutaneous erosions. The severity of the disease, as well as the mucosal lesions, is believed to be directly proportional to the levels of desmoglein 3. Milder forms of pemphigus (like foliacious and erythematoses) are more anti-desmoglein 1 heavy.

The disease arises most often in middle-aged or older people, usually starting with a blister that ruptures easily. It can also start with blisters in the mouth. The lesions can become quite extensive.

Diagnosis[edit]

Because it is a rare disease, diagnosis is often complicated and takes a long time. Early in the disease patients may have erosions in the mouth or blisters on the skin. These blisters can be itchy or painful. Theoretically, the blisters should demonstrate a positive Nikolsky's sign, in which the skin sloughs off from slight rubbing, but this is not always reliable. The gold standard for diagnosis is a punch biopsy from the area around the lesion that is examined by direct immunofluorescent staining, in which cells are acantholytic, that is, lacking the normal intercellular connections that hold them together. These can also be seen on a Tzanck smear. These cells are basically rounded, nucleated keratinocytes formed due to antibody mediated damage to cell adhesion protein desmoglein.

Pemphigus vulgaris is easily confused with impetigo and candidiasis. IgG4 is considered pathogenic. The diagnosis can be confirmed by testing for the infections that cause these other conditions, and by a lack of response to antibiotic treatment.[8]

Treatment[edit]

Corticosteroids and other immunosuppressive medications have historically been employed to reduce pemphigus symptoms, yet steroids are associated with serious and long-lasting side effects and their use should be limited as much as possible. Intravenous immunoglobulin, mycophenolate mofetil, methotrexate, azathioprine, and cyclophosphamide have also been used with varying degrees of success.

An established alternative to steroids are monoclonal antibodies such as rituximab, which are increasingly being used as first-line treatment. In numerous case series, many patients achieve remission after one cycle of rituximab. Treatment is more successful if initiated early on in the course of disease, perhaps even at diagnosis. Rituximab treatment combined with monthly IV immunoglobulin infusions has resulted in long-term remission with no recurrence of disease in 10 years after treatment was halted.[9] This was a small trial study of 11 patients with 10 patients followed to completion.

Research[edit]

Research into using genetically modified T-cells to treat pemphigus vulgaris in mice was reported in 2016.[10][11] Rituximab indiscriminately attacks all B cells, which reduces the body's ability to control infections. In the experimental treatment, human T cells are genetically engineered to recognize only those B cells that produce antibodies to desmoglein 3.

See also[edit]

References[edit]

  1. ^ Cholera M, Chainani-Wu N (June 2016). "Management of Pemphigus Vulgaris". Advances in Therapy. 33 (6): 910–58. doi:10.1007/s12325-016-0343-4. PMC 4920839Freely accessible. PMID 27287854. 
  2. ^ Beigi PK (2018). A Clinician's Guide to Pemphigus Vulgaris. Springer, Cham. pp. 13–13. doi:10.1007/978-3-319-67759-0_3. ISBN 978-3-319-67758-3. 
  3. ^ King DF, Holubar K (October 1983). "History of pemphigus". Clinics in Dermatology. 1 (2): 6–12. PMID 6400552. 
  4. ^ Gupta VK, Kelbel TE, Nguyen D, Melonakos KC, Murrell DF, Xie Y, Mullard A, Reed PL, Seiffert-Sinha K, Sinha AA (July 2011). "A globally available internet-based patient survey of pemphigus vulgaris: epidemiology and disease characteristics". Dermatologic Clinics. 29 (3): 393–404, vii–iii. doi:10.1016/j.det.2011.03.016. PMID 21605804. 
  5. ^ a b c "Pathogenesis, clinical manifestations, and diagnosis of pemphigus". www.uptodate.com. Retrieved 2017-04-03. 
  6. ^ A Clinician's Guide to Pemphigus Vulgaris, https://www.springer.com/gp/book/9783319677583
  7. ^ Venugopal SS, Murrel DF. Diagnosis and clinical feature of pemphigus vulgaris. Dermatol Clin. 2011;29(3):373–80.
  8. ^ Kaplan DL (2009). "Dermclinic". Consultant. 49 (3). 
  9. ^ Ahmed AR, Kaveri S, Spigelman Z (December 2015). "Long-Term Remissions in Recalcitrant Pemphigus Vulgaris". The New England Journal of Medicine. 373 (27): 2693–4. doi:10.1056/NEJMc1508234. PMID 26716930. 
  10. ^ Gallagher J (2016-07-01). "'Civil war' in immune system can fight disease". BBC News, Health. Retrieved 2016-07-01. 
  11. ^ Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS (July 2016). "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease". Science. 353 (6295): 179–84. doi:10.1126/science.aaf6756. PMC 5343513Freely accessible. PMID 27365313. 

External links[edit]

Classification
External resources